Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response ...

(RTTNews) - Coherus BioSciences, Inc. (CHRS), Wednesday announced final data from its Phase 2 study evaluating casdozokitug in combination with atezolizumab and bevacizumab in patients with ...

With better risk stratification, clinicians may be able to optimize medical management of patients with chronic HBV who don’t ...

Announcing a new publication for Acta Materia Medica journal. Epithelial cell adhesion molecule (EpCAM) is a biomarker for epithelial cell-derived tumors.

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

However, the specific role of EpCAM itself in early-stage hepatocellular carcinoma progression remains unclear, and small molecules targeting EpCAM have not yet been reported. Molecular docking ...

SBRT showed superiority over radiofrequency ablation in local progression-free survival and tumor control in small HCC but ...

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few—in ...

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

FLC is a rare liver cancer with unique genetic traits, often misdiagnosed until advanced. New research and a clinical trial ...